Zogenix Inc logo

ZGNX - Zogenix Inc Share Price

$19.12 -0.1  -0.6%

Last Trade - 9:00pm

Mid Cap
Market Cap £764.3m
Enterprise Value £562.3m
Revenue £18.6m
Position in Universe 2753rd / 6851
Unlock ZGNX Revenue
Relative Strength (%)
1m +2.31%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -40.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
27.2 28.9 9.82 0.000 3.65 13.6 86.5 222.6 -12.9%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2021, Zogenix,Inc. revenues increased from $1.2M to $13.7M. Net lossincreased from $25.8M to $55.6M. Revenues reflectCollaboration revenue increase of 7% to $1.3M. Higher netloss reflects Other income (expense) decrease from $20M(income) to $397K (expense), Selling, General &Administrative Exp increase of 50% to $26.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ZGNX Revenue Unlock ZGNX Revenue

Net Income

ZGNX Net Income Unlock ZGNX Revenue

Normalised EPS

ZGNX Normalised EPS Unlock ZGNX Revenue

PE Ratio Range

ZGNX PE Ratio Range Unlock ZGNX Revenue

Dividend Yield Range

ZGNX Dividend Yield Range Unlock ZGNX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ZGNX EPS Forecasts Unlock ZGNX Revenue
Profile Summary

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.

Last Annual December 31st, 2020
Last Interim March 31st, 2021
Incorporated May 11, 2006
Public Since November 23, 2010
No. of Shareholders: 9
No. of Employees: 218
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 55,812,590
Free Float (0.0%)
Eligible for
ZGNX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ZGNX
Upcoming Events for ZGNX
Thursday 27th May, 2021
Zogenix Inc Annual Shareholders Meeting
Friday 28th May, 2021 Estimate
Zogenix Inc Annual Shareholders Meeting
Tuesday 3rd August, 2021 Estimate
Q2 2021 Zogenix Inc Earnings Release
Monday 8th November, 2021 Estimate
Q3 2021 Zogenix Inc Earnings Release
Frequently Asked Questions for Zogenix Inc
What is the Zogenix Inc share price?

As of 9:00pm, shares in Zogenix Inc are trading at $19.12, giving the company a market capitalisation of £764.3m. This share price information is delayed by 15 minutes.

How has the Zogenix Inc share price performed this year?

Shares in Zogenix Inc are currently trading at $19.12 and the price has moved by -25.54% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Zogenix Inc price has moved by -47.73% over the past year.

What are the analyst and broker recommendations for Zogenix Inc?

Of the analysts with advisory recommendations for Zogenix Inc, there are there are currently 5 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Zogenix Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Zogenix Inc next release its financial results?

Zogenix Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Zogenix Inc dividend yield?

Zogenix Inc does not currently pay a dividend.

Does Zogenix Inc pay a dividend?

Zogenix Inc does not currently pay a dividend.

When does Zogenix Inc next pay dividends?

Zogenix Inc does not currently pay a dividend.

How do I buy Zogenix Inc shares?

To buy shares in Zogenix Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Zogenix Inc?

Shares in Zogenix Inc are currently trading at $19.12, giving the company a market capitalisation of £764.3m.

Where are Zogenix Inc shares listed? Where are Zogenix Inc shares listed?

Here are the trading details for Zogenix Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: ZGNX
What kind of share is Zogenix Inc?

Based on an overall assessment of its quality, value and momentum, Zogenix Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Zogenix Inc share price forecast 2021?

Shares in Zogenix Inc are currently priced at $19.12. At that level they are trading at 0.153% discount to the analyst consensus target price of 0.00.

Analysts covering Zogenix Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.45 for the next financial year.

How can I tell whether the Zogenix Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zogenix Inc. Over the past six months, the relative strength of its shares against the market has been -20.49%. At the current price of $19.12, shares in Zogenix Inc are trading at -7.74% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Zogenix Inc PE Ratio?

We were not able to find PE ratio data for Zogenix Inc.

Who are the key directors of Zogenix Inc?

Zogenix Inc's management team is headed by:

Stephen Farr - PRE
Cam Garner - CHM
Louis Bock - IND
Erle Mast - IND
Bradley Galer - EVP
James Breitmeyer - IND
Gail Farfel - EVP
Michael Smith - CFO
Ashish Sagrolikar - EVP
Shawnte Mitchell - EVP
Caroline Loewy - IND
Mary Stutts - IND
Who are the major shareholders of Zogenix Inc?

Here are the top five shareholders of Zogenix Inc based on the size of their shareholding:

RA Capital Management, LP Hedge Fund
Percentage owned: 9.58% (5.35m shares)
Cadian Capital Management LP Hedge Fund
Percentage owned: 9.44% (5.27m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 7.38% (4.12m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 7.37% (4.11m shares)
Morgan Stanley & Co. LLC Research Firm
Percentage owned: 5.61% (3.13m shares)
Similar to ZGNX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.